Category Archives: Data Exclusivity

Rethinking IP in the TPP: Canadian Government Plays Key Role in Suspending Unbalanced Patent and Copyright Rules

Source: http://www.michaelgeist.ca/2017/11/rethinking-ip-in-the-tpp/ Years of disappointment in trade negotiations have left many Canadian intellectual property watchers hoping for the best, but expecting the worst when it comes to the IP provisions in trade deals. In earlier talks, Canadian negotiators would often advocate … Continue reading

Posted in Biologics/Biosimilars, Data Exclusivity, Patent Term Extension, TPP, TRIPS, TRIPS plus, Uncategorized | Leave a comment

Time for costly medicine monopolies to go from TPP trade talks

Source: Conversation.com |November 9, 2017 Negotiators from 11 countries have been racing to resurrect the near-dead Trans-Pacific Partnership Agreement before the Asia-Pacific Economic Cooperation (APEC) summit this weekend. The latest plan to get the controversial trade deal up and running … Continue reading

Posted in Biologics/Biosimilars, Data Exclusivity, Patent, TPP, Uncategorized | Leave a comment

India to oppose anti-generics proposals at RCEP meet

Source: LiveMint India stands firm in opposing proposals that could hinder global access to affordable generic drugs and life-saving vaccines South Korea and Japan have been pushing for proposals to extend drug and vaccine patent terms, a move that is … Continue reading

Posted in Data Exclusivity, Generics, Patent, Patent Term Extension, Regional Comprehensive Economic Partnership, TRIPS, TRIPS plus, TRIPS&IP rights, Uncategorized, WTO | Leave a comment

Global access to affordable medicines should not be restricted

MSF has witnessed the negative impact of monopoly pricing on life-saving medicines and vaccines in its medical projects all over the world. Courtesy- ajp.com.au As 16 countries negotiating the Regional Comprehensive Economic Partnership (RCEP) agreement meet this week in Incheon, … Continue reading

Posted in Data Exclusivity, Generics, Patent, Patent Term Extension, Regional Comprehensive Economic Partnership, TRIPS&IP rights, Uncategorized, WTO | Leave a comment

India Will Not Cross Red Lines on Generic Drugs in RCEP, but Stay Vigilant, Say Officials

Source: The Wire Healthcare watchers are calling on India to resist the free trade agreement’s provisions which could compromise India’s ability to keep supplying cheaper generic drugs to the world. Hundreds of government officials and activists huddle separately in South … Continue reading

Posted in Data Exclusivity, Generics, IPR, Patent, Patent Term Extension, Regional Comprehensive Economic Partnership, Uncategorized | Leave a comment

Stakeholder Intervention at 19th RCEP negotiations round- Chalermsak Kittitrakul, network of PLHIV & AIDS, Peoples’ Health Systems Movement, and FTA Watch

Thai CSOs’ comments on the data exclusivity measure in the RCEP given at the stakeholder consultation meeting hosted by the RCEP trade negotiators at Hyderabad, India on July 25, 2017. Good afternoon, trade negotiators of the ASEAN countries and the … Continue reading

Posted in Data Exclusivity, IPR, Regional Comprehensive Economic Partnership, TRIPS, TRIPS plus, TRIPS&IP rights, Uncategorized | Leave a comment

What’s at stake in Hyderabad

By Feroz Ali, The Hindu | July 28, 2017 India must counter Japan’s U.S.-style pressure at the RCEP talks and ensure affordable generic medicines Leaked texts are like leaked gases — you may never find the one responsible for it, … Continue reading

Posted in Data Exclusivity, IP Rights, IPR, Patent, Patent Term Extension, Regional Comprehensive Economic Partnership, TRIPS, TRIPS plus, Uncategorized | Leave a comment